American journal of hypertension
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.
The antihypertensive efficacy and safety of darusentan, a new selective endothelin, antagonist was investigated. ⋯ These data, the first, suggest the therapeutic benefit of selective endothelinA receptor antagonism in human hypertension.